• August 4, 2020

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Odessa American: Business

e-Edition Subscribe

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Print
Font Size:
Default font size
Larger font size

Posted: Friday, July 10, 2020 8:01 am | Updated: 8:31 am, Fri Jul 10, 2020.

ROCKVILLE, Md.--(BUSINESS WIRE)--Jul 10, 2020--

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on July 6, 2020 of a non-qualified stock option award to purchase an aggregate of 12,200 shares of its common stock to a new employee. The options were granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by the new employee. The options are subject to the terms and conditions of a stock option agreement covering the grant and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.

The stock option award has an exercise price equal to the closing price of the Company’s common stock on July 06, 2020. The options have a ten-year term and vest over four years, with one-fourth of the shares vesting one year after the grant date, and the balance of the shares vesting in a series of thirty-six successive equal monthly installments measured from the first anniversary of the grant date, subject to the new employee’s continued service with the Company through the applicable vesting dates.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with two late-stage clinical development programs and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML under breakthrough therapy designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in SCD. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the clinical development and potential benefits and impact of the Company’s drug candidates. These forward-looking statements include those relating to the planned clinical development of the Company’s product candidates, including the presentation of data from preclinical studies and clinical trials. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2020, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200710005249/en/

CONTACT: GlycoMimetics

Investor:

Shari Annes

Phone: 650-888-0902

Email:sannes@annesassociates.com

Media:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email:jamielacey@presscommpr.com

KEYWORD: MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: GlycoMimetics, Inc.

Copyright Business Wire 2020.

PUB: 07/10/2020 09:00 AM/DISC: 07/10/2020 09:00 AM

http://www.businesswire.com/news/home/20200710005249/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
79°
Humidity: 46%
Winds: ESE at 12mph
Feels Like: 80°

Your Extended Forecast

Tomorrow

weather
High 94°/Low 71°
Mostly clear. Lows overnight in the low 70s.

tuesday

weather
High 102°/Low 75°
A few clouds. Highs 100 to 104F and lows in the mid 70s.

wednesday

weather
High 104°/Low 75°
More sun than clouds. Highs 102 to 106F and lows in the mid 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.